Research programme: glycosylation inhibitors - Infinity Pharmaceuticals/Seikagaku
Latest Information Update: 16 Mar 2009
Price :
$50 *
At a glance
- Originator Infinity Pharmaceuticals; Seikagaku Corporation
- Class
- Mechanism of Action Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 31 Dec 2008 Discontinued - Preclinical for Undefined indication in Japan (unspecified route)
- 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
- 28 Nov 2005 Preclinical trials in Undefined in Japan (unspecified route)